Navigating the red: Diagnostic dilemma of erythema and diffuse body rash post- intrathecal baclofen pump implantation

TL;DR

This paper discusses the challenges in diagnosing skin reactions after intrathecal baclofen pump implantation and emphasizes the need for careful patient evaluation.

Contribution

The paper highlights the importance of thorough patient history and multidisciplinary expertise in managing post-implant skin reactions.

Findings

Skin reactions post-implant can be due to localized or systemic infections.

Accurate diagnosis is crucial to avoid unnecessary device removal.

Collaboration with subspecialists improves patient care outcomes.

Abstract

Intrathecal drug delivery system (IDDS) infections can be localized to the pump pocket site and/or the catheter insertion site or become systemic, all potentially resulting in IDDS explant. Given the well-established effectiveness of IDDS for chronic non-cancer pain, cancer-associated pain, and spasticity, clinicians must differentiate between localized and systemic post-operative IDDS infections, as well as identify other causes of post-surgical skin irritation while avoiding unnecessary device explanation and therapy interruption.

In this letter-to-the-editor, we describe and discuss the importance of taking a thorough patient history and utilizing both critical clinical decision-making as well as expertise from other subspecialists to care for IDDS patients and navigate problematic skin reactions following implant.

Figures